← Scoopfeeds — Intelligent news, curated.
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
business

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

Yahoo Finance · Jun 3, 2026, 4:50 PM · Also reported by 2 other sources

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Benchmark reiterates Halozyme stock Buy rating on long-term potential Investing.com Shake Shack stock under pressure as analysts cut ratings following lowered outlook

More in business

Bloomberg Markets
Diller Bids For Rest of MGM Resorts After Overhauling IAC
Investing.com
ZoomInfo options trading surges to over 20,000 contracts
CoinDesk
New DeFi entrant widens field of crypto political campaign funds as elections loom
Investing.com
Five countries elected to UN Security Council; Germany misses out
CoinDesk
Bitcoin isn't crashing because of Saylor, it's losing the momentum trade
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop